Evidence map›Paper›PMID 36945511›Full record

ArticleResearch square2023

Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma.

Imani Bijou, Yang Liu, Dong Lu, Jianwei Chen, Shelby Sloan, Lapo Alinari, David M Lonard, Bert W O'Malley, Michael Wang, Jin Wang

Open access · greenFull text readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Imani BijouBaylor College of Medicine.
Yang LiuThe University of Texas MD Anderson Cancer Center.
Dong LuBaylor College of Medicine.
Jianwei ChenBaylor College of Medicine.
Shelby SloanThe James Cancer Hospital and Solove Research Institute, The Ohio State University.
Lapo AlinariThe James Cancer Hospital and Solove Research Institute, The Ohio State University.
David M LonardBaylor College of Medicine.
Bert W O'MalleyBaylor College of Medicine.
Michael WangThe University of Texas MD Anderson Cancer Center.
Jin WangBaylor College of Medicine.
Baylor College of Medicine · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USThe University of Texas MD Anderson Cancer Center · US

Funding

Initiative for Maximizing Student Development (IMSD) ProgramR25GM056929 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI PEREIRA, FRED A · 1998 to 2023
$12.4M
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell MalignanciesR01CA250503 · NCI · BAYLOR COLLEGE OF MEDICINE · PI WANG, JIN, WANG, MICHAEL · 2020 to 2024
$3.4M
Drugging the Undruggable Coactivators using Small Molecule InhibitorsR01CA207701 · NCI · BAYLOR COLLEGE OF MEDICINE · PI WANG, JIN · 2017 to 2021
$2.5M
Baylor College of Medicine Initiative for Maximizing Student DevelopmentT32GM152777 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI PANGAS, STEPHANIE A., PEREIRA, FRED A · 2024 to 2024
$547k
NCI NIH HHS R01 CA207701NCI NIH HHS R01 CA250503NIGMS NIH HHS R25 GM056929NIGMS NIH HHS T32 GM152777
6 · The paper itself

Abstract

Mantle cell lymphoma (MCL) is a heterogeneous disease with a poor prognosis. Despite years of research in MCL, relapse occurs in patients with current therapeutic options necessitating the development of novel therapeutic agents. Previous attempts to pharmacologically inhibit SRC-3 show effectiveness

Indexed as

antitumor activitydrug resistanceMantle cell lymphomaSRC-3

Identifiers

PMID36945511
PMCPMC10029087
OpenAlexW4323655303

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read25
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.